CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction.
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法在治疗多种血液系统恶性肿瘤方面取得了显著的治疗成功。然而,高复发率和体内持久性差,部分由 CAR-T 细胞耗竭引起,仍然是 CAR-T 疗法的重要障碍。CAR-T 耗竭的机制以及如何减轻耗竭以实现更好的治疗效果,在很大程度上仍不清楚。
在本研究中,我们最初观察到 CAR-T 细胞在体外与肿瘤细胞共培养后表现出快速分化和耗竭增加,随后进行了单细胞 ATAC-seq,以描绘 CAR-T 细胞在肿瘤细胞刺激过程中染色质可及性的全面动态图谱。对差异染色质可及区域和基序可及性的分析揭示,转录因子在每种细胞类型中各不相同,并重建了一个协调的调控网络来驱动 CAR-T 耗竭。
此外,我们对患者来源的 CAR-T 细胞进行了 scATAC-seq,并确定 BATF 和 IRF4 是 CAR-T 细胞耗竭的关键调控因子。
最后,敲低 BATF 或 IRF4 增强了杀伤能力,抑制了耗竭,并延长了 CAR-T 细胞在体内的持久性。总之,我们的研究揭示了 CAR-T 耗竭的表观遗传调控机制,并为 CAR-T 工程以实现更好的临床治疗获益提供了新的见解。
Chimeric antigen receptor T cells (CAR-T) therapy has achieved remarkable therapeutic success in treating a variety of hematopoietic malignancies.
However, the high relapse rate and poor in vivo persistence, partially caused by CAR-T cell exhaustion, are still important barriers against CAR-T therapy. It remains largely elusive on the mechanisms of CAR-T exhaustion and how to attenuate exhaustion to achieve better therapeutic efficacy.
In this study, we initially observed that CAR-T cells showed rapid differentiation and increased exhaustion after co-culture with tumor cells in vitro, and then performed single-cell ATAC-seq to depict the comprehensive and dynamic landscape of chromatin accessibility of CAR-T cells during tumor cell stimulation. Analyses of differential chromatin accessible regions and motif accessibility revealed that TFs were distinct in each cell type and reconstituted a coordinated regulatory network to drive CAR-T exhaustion.
Furthermore, we performed scATAC-seq in patient-derived CAR-T cells and identified BATF and IRF4 as pivotal regulators in CAR-T cell exhaustion.
Finally, knockdown of BATF or IRF4 enhanced the killing ability, inhibited exhaustion, and prolonged the persistence of CAR-T cells in vivo.
Together, our study unraveled the epigenetic regulatory mechanisms of CAR-T exhaustion and provided new insights into CAR-T engineering to achieve better clinical treatment benefits.
MEMBER ACCOUNT
登录成功会直接打开下一页。